Effects of Semaglutide on Glucose and Lipid Metabolism,Liver Function,and Liver Fibrosis in Type 2 Diabetes Patients with NAFLD
Objective To investigate the effects of semaglutide on glucose and lipid metabolism,liver function,and liver fibrosis in type 2 diabetes mellitus (T2DM) patients with nonalcoholic fatty liver disease (NAFLD). Methods A prospective randomized controlled study was conducted on 90 T2DM patients with NAFLD admitted to the Department of Endocrinology at Heilongjiang Provincial Hospital from January 2023 to December 2023. The patients were randomly divided into three groups of 30 each using the random number table method. All groups received a metformin-based hypoglycemic regimen. One group received a normal diet,another group received a low-carbohydrate diet (LCD),and the semaglutide group was treated with semaglutide injec-tions on the basis of a normal diet. The glucose and lipid metabolism,liver function,and liver fibrosis indicators of the three groups were compared. Results After treatment,the FPG,2 hPG,HbA1c,TC,TG,and LDL-C levels in the semaglutide group were lower than those in the LCD group and the normal diet group,while HDL-C levels were higher than those in the LCD group and the normal diet group (all P<0.05). After treatment,the levels of ALT,AST,and γ-GT in the semaglutide group were lower than those in the LCD group and the normal diet group (all P<0.05). Additionally,the levels of PC Ⅲ,LN,HA,and FIB-4 index in the semaglutide group were lower than those in the LCD group and the normal diet group (all P<0.05). Conclusion Semaglutide may effectively improve glucose and lipid metabolism,liver function indicators,and inhibit the progression of liver fibrosis in T2DM patients with NAFLD.
Type 2 diabetesNAFLDSemaglutideGlucose and lipid metabolismLiver functionLiver fibrosis
万方数据
维普
